In this episode of Drug Digest, experts from Sanofi, GxP Frame, and Open Biopharma explain how AI is transforming drug discovery, manufacturing, and workforce strategy and how strategic partnerships ...
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, ...
Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied ...
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs ...
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, ...
As publishers and research platforms such as Reaxys and Springer Nature build application programming interface (API) access ...
The expansion plans to increase Vectura’s DPI dosage form development, specifically its unit dose and multi-dose inhalers, and integrated device design and manufacturing for customer programs.
Thermo Fisher Scientific announced it is showcasing new and expanded services at CPHI Milan, which is happening from October 6-8, 2026. The company will be presenting new drug dev ...
Access Part 1 of this interview in which Scarboro explains why real-world usability belongs at product definition. Access ...
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require. PharmTech AI Pulse Check episode 2 covers AI data ...
The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor ...
The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results